Search results: (10000)
News Reversal of Dabigatran Effects with Idarucizumab in Patients Requiring Urgent Procedures: Subanalysis of the RE-VERSE AD Study
The effect of idarucizumab as a reversal agent in patients treated with dabigatran in situations requiring urgent surgery or other invasive procedures was evaluated in a subanalysis from the RE-VERSE AD study published in 2021.
News Comparable Long-term Safety of Tofacitinib and Biologics in RA Treatment – Data from a US Registry
An analysis of the long-term safety profile of tofacitinib in real clinical practice was published in the journal of the American College of Rheumatology (ACR). Patients with rheumatoid arthritis (RA) who started treatment with tofacitinib showed a similar frequency of predefined adverse events of special interest compared to a cohort treated with biological disease-modifying antirheumatic drugs (bDMARDs).
News HAE Junior Helps Improve the Quality of Life for Pediatric Patients
Living with hereditary angioedema (HAE) brings chronic health issues, long-term psychological stress, and a lifelong threat of death. Initial symptoms of HAE appear during childhood or adolescence. Many patients, however, remain misdiagnosed for a long time. The patient organization HAE Junior strives for a better quality of life for patients with this condition by improving awareness and access to modern therapy.
News Cost-Effectiveness of Preparations Used to Stop Bleeding in Patients with AHA
Choosing the right preparation to manage acute bleeding in patients with acquired hemophilia A is not always simple. An interesting perspective and recommendations are provided by a model analysis assessing the cost and effectiveness of individual available preparations.
News Risk of Developing Inhibitors in People with Milder Forms of Hemophilia
Moderate and mild hemophilia A differ from the severe form not only in clinical course and bleeding risk, but also in the risk of developing neutralizing antibodies (inhibitors).
News Efficacy and Safety of Dupilumab in the Treatment of Atopic Dermatitis in Adolescents
In the pediatric population, atopic dermatitis (AD) has a relatively high prevalence, but therapeutic options are often limited. The following article offers a summary of the results from a clinical study published last year focusing on the efficacy and safety of dupilumab in adolescent patients with moderate to severe AD that is not adequately controlled by topical therapy.
News Association between Cardiovascular Risk Factors and Cognitive Disorders in Patients with Schizophrenia
Schizophrenia is a disease characterized by a certain degree of cognitive impairment, but also an increased risk of cardiovascular diseases, which are often the cause of deteriorating cognitive functions in the general population. The aim of a large meta-analysis was to elucidate the association between cardiovascular risk factors and cognitive disorders in patients with schizophrenia and schizoaffective disorder, based on the results of a previous smaller study that demonstrated an association between metabolic syndrome, diabetes, and cognitive disorders.
News Does Teriflunomide Bloom at Every Age?
What impact does age have on the effectiveness of multiple sclerosis (MS) therapy in real-world clinical practice? How do the outcomes differ for patients treated with teriflunomide considering their age and previous therapy? The authors of a study published this year in the journal Therapeutic Advances in Neurological Disorders focused on the efficacy and safety of teriflunomide in real-world clinical practice with regard to age and prior treatment.
News Prevention of Symptomatic Skeletal Events in Postmenopausal Women with Advanced ER-Positive Breast Cancer
Advanced breast cancer with the presence of estrogen receptors is one of the most common cancers worldwide. Hormonal treatment for this malignancy is highly effective, but it is accompanied by risks such as symptomatic skeletal events (SSE). However, this undesired anti-estrogen effect can be prevented by administering appropriate antiresorptive drugs. A retrospective study by Hong Kong researchers focused on the effectiveness of these drugs in clinical practice.
News Seventy-day Shedding of SARS-CoV-2 in an Immunocompromised Patient with CLL – A Case Study
A team of American and British experts published the case of a 71-year-old woman with chronic lymphocytic leukemia (CLL) and hypogammaglobulinemia who tested positive for SARS-CoV-2. Despite an asymptomatic course of infection, virus shedding was documented for up to 10 weeks, and viral RNA presence was detected for 15 weeks after the initial detection. The longest recorded virus shedding at the time of the article's publication was 20 days after the first positive test result.
News San Antonio: Results of Breast Cancer Treatment with Combination of Pertuzumab, Trastuzumab, and AI After 6 Years
The virtual conference dedicated to breast cancer, which took place December 8–11 in San Antonio, USA (San Antonio Breast Cancer Symposium; SABCS 2020), presented, among other things, the results of the final analysis of the multicenter randomized open-label PERTAIN study.
News Turoctocog Alfa Pegol and Its Impact on Health-Related Quality of Life
The presented work is based on the results of studies that evaluated how the administration of turoctocog alfa pegol affects the quality of life in individuals with severe hemophilia A. The obtained data also reflect the level of patient satisfaction with this treatment.
News Insufficient dosing of enoxaparin is common in patients post-orthopedic surgery and increases the risk of thromboembolic disease
Orthopedic and traumatological procedures involving the pelvis and lower limbs are associated with a significant increase in the risk of thromboembolic disease. Therefore, prophylaxis with anticoagulants is recommended in the perioperative and postoperative period for these procedures. The most commonly administered anticoagulants are low molecular weight heparins, among which enoxaparin is included. A recently published study by authors from the University of Utah focused on insufficient dosing of enoxaparin and its impact on the development of thromboembolic disease within 90 days following the procedure.
News Treatment of Comorbidities of Atopic Dermatitis in One Go and Where to Refer Candidates for Biologic Therapy
Patients suffering from atopic dermatitis (AD) along with allergic comorbidities typically require a fairly complex pharmacotherapy to manage their difficulties. However, their everyday lives can be significantly simplified with biological therapy.
News Do antiglaucoma drugs induce inflammation and irritation on the eye surface? Results of a 2-year randomized study
Eye drops for glaucoma treatment may contain preservatives responsible for eye irritation and possibly chronic inflammation. The study presented below is the first to compare the profile of inflammatory cytokines and eye irritation in patients using topical antiglaucoma drugs with and without preservatives.
News Protective Effect of SGLT2 Inhibitors on Heart Muscle Function - Findings from a Recent Meta-analysis
Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) primarily offer the ability to achieve very good glycemic control with a low risk of hypoglycemia. Their undeniable advantage, however, is their cardiovascular safety and renoprotective effect. The impact of gliflozins on heart functions has already been the subject of many studies, the findings of which are summarized in a recently published meta-analysis.
News How Will the New Player in Dyslipidemia Therapy Change the "Rules of the Game"?
Inclisiran, as an innovative drug indicated for adult patients with primary hypercholesterolemia or mixed dyslipidemia, was registered in the European Union at the end of 2020. Internists and cardiologists can now share their first experiences with this therapy in real practice. Case reports from the Czech Republic have also been published in specialized literature.
News Pharmacokinetic Comparison of Two EHL Products in Hemophilia A
According to a Canadian study published last year, certain pharmacokinetic differences were observed between two extended half-life factors.
News Monitoring of Joint Health is an Important Part of Hemophilia Care
Joint health has become a key aspect of the quality of life for people with hemophilia. The possibilities of monitoring early joint damage in hemophiliacs were evaluated in a recently published British study.
News Rurioctocog alfa pegol in previously treated patients with severe hemophilia A: What findings did the long-term continuation study bring?
Rurioctocog alfa pegol (Adynovi) is a recombinant coagulation factor VIII modified by pegylation, which results in an approximately 1.5× prolonged biological half-life compared to standard half-life FVIII. Previous studies have already confirmed the favorable profile of this drug in prophylaxis for patients with hemophilia A. Recently published results of a prospective multicenter continuation study in children and adult patients under 75 years old with severe hemophilia A (baseline FVIII level < 1%) were based on an observation period averaging 2.2 years.
News Issues of Adherence to Thromboprophylaxis with Enoxaparin in Patients with Sickle Cell Disease
Thromboembolic disease is one of the common complications in patients with sickle cell disease (SCD). However, a recently published study shows that patient adherence to prescribed thromboprophylaxis is not very high.
News Safety of Urgent Initiation of Peritoneal Dialysis
In case of urgent need for kidney function replacement, hemodialysis (HD) with a temporary venous catheter has long been the standard solution. However, it has several disadvantages such as increased mortality or the risk of bacteremia and central venous stenosis. Additionally, multiple procedures are needed to create a permanent venous access. Therefore, there is a growing global interest in urgently initiated peritoneal dialysis (PD), with several clinical studies attesting to its safety, efficacy, and feasibility. However, little has been known about early PD complications and the long-term prognosis of patients in terms of technical and infectious complications.
News Fresh data from real clinical practice on targeted treatment of RA with etanercept: Should therapy be changed after 12 weeks due to insufficient response?
A recently published German study investigated, among other things, what percentage of patients with rheumatoid arthritis (RA) achieve remission or low disease activity after a certain period of etanercept treatment in real clinical practice.